Literature DB >> 17251340

Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Jerzy Lasota1, Bartosz Wasag, Sonja E Steigen, Janusz Limon, Markku Miettinen.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal mesenchymal tumors driven by KIT or PDGFRA mutations. A majority of these mutations affect KIT exon 11 and represent deletions or point mutations, but insertions and duplications have also been reported. The latter have been found exclusively in the 3' part of KIT exon 11. Reported frequency of duplications varies, and a higher frequency has been reported in studies based on frozen tissue. Recently, we have hypothesized that in some cases, the duplications might remain undetected in formalin-fixed, paraffin-embedded GISTs because of the preferential polymerase chain reaction (PCR) amplification of wild-type KIT over the mutant allele. In this study, 16 GISTs initially diagnosed as a wild-type KIT were evaluated using PCR assay amplifying only the 3' part of KIT exon 11, the region commonly affected by duplications. Denaturing high-pressure liquid chromatography and direct sequencing analyses revealed duplications in 4 (25%) of 16 analyzed cases. Use of the PCR assay amplifying the specific region affected by duplications and yielding 129 bp in wild-type KIT can substantially improve the detection of these mutations in formalin-fixed, paraffin-embedded GISTs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251340      PMCID: PMC1867433          DOI: 10.2353/jmoldx.2007.060104

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  37 in total

1.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.

Authors:  J Lasota; A Wozniak; M Sarlomo-Rikala; J Rys; R Kordek; A Nassar; L H Sobin; M Miettinen
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes.

Authors:  Paul Emmerson; Julie Maynard; Siân Jones; Rachel Butler; Julian R Sampson; Jeremy P Cheadle
Journal:  Hum Mutat       Date:  2003-02       Impact factor: 4.878

3.  Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.

Authors:  Florian Haller; Bastian Gunawan; Anja von Heydebreck; Stefanie Schwager; Hans-Jürgen Schulten; Judith Wolf-Salgó; Claus Langer; Giuliano Ramadori; Holger Sültmann; László Füzesi
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

4.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authors:  B P Rubin; S Singer; C Tsao; A Duensing; M L Lux; R Ruiz; M K Hibbard; C J Chen; S Xiao; D A Tuveson; G D Demetri; C D Fletcher; J A Fletcher
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

5.  c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.

Authors:  Eva Wardelmann; Iris Neidt; Erhard Bierhoff; Nicola Speidel; Christoph Manegold; Hans-Peter Fischer; Ulrich Pfeifer; Torsten Pietsch
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

6.  Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.

Authors:  Yon Rak Choi; Hyunki Kim; Hyun Ju Kang; Nam-Gyun Kim; Jung Jin Kim; Kang-Sik Park; Young-Ki Paik; Hyun Ok Kim; Hoguen Kim
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

7.  Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.

Authors:  Cristina R Antonescu; Gunhild Sommer; Lisa Sarran; Sylvia J Tschernyavsky; Elyn Riedel; James M Woodruff; Mark Robson; Robert Maki; Murray F Brennan; Marc Ladanyi; Ronald P DeMatteo; Peter Besmer
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 8.  Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

View more
  3 in total

1.  A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.

Authors:  Isabelle Hostein; Maria Debiec-Rychter; Sylvianne Olschwang; Pierre-Paul Bringuier; Louisa Toffolati; David Gonzalez; Sébastien Forget; Fabienne Escande; Lucyna Morzuch; Elena Tamborini; Nicolas Faur; Silvana Pilotti; Paolo Dei Tos; Jean-François Emile; Jean-Michel Coindre
Journal:  J Gastroenterol       Date:  2011-02-01       Impact factor: 7.527

2.  Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Authors:  Kjetil Søreide; Oddvar M Sandvik; Jon Arne Søreide; Einar Gudlaugsson; Kjersti Mangseth; Hans Kristian Haugland
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

3.  Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.

Authors:  Alenka Bombac; Branko Zakotnik; Marina Bucic; Vita Setrajcic Dragos; Barbara Gazic; Vida Stegel; Gasper Klancar; Srdjan Novakovic
Journal:  Int J Oncol       Date:  2020-03-26       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.